Dec 23, 2021

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

Apr 15, 2021

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

Feb 10, 2021

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

Jan 12, 2021

Louis Pascarella Appointed Chief Executive Officer of Innocoll